MedTrace Logo

Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee

NCT06021444 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2023-09-21

No results posted yet for this study

Summary

To prove the non-inferiority of DKM420 by evaluating the injecting efficacy and safety DKM 420 and control for patients who have osteoarthritis of Knee.

Conditions

  • Osteoarthritis of Knee

Interventions

DEVICE

DKM420

A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.

DEVICE

Conjuran

A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.

Sponsors & Collaborators

  • Dongkook Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-30
Primary Completion
2023-06-01
Completion
2023-07-18

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021444 on ClinicalTrials.gov